Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MOF Wants Generic Drug Share to Reach European, US Levels: Budget Examiner Shinkawa
August 8, 2012
- Talks between Health Minister, Plaintiff/Lawyer Groups Break Down on 3rd-Party Organization
August 7, 2012
- PAFSC’s First Committee Recommends Orphan Drug Designation for LAL Deficiency Treatment
August 7, 2012
- PAFSC’s First Committee Recommends Approval for Takeda’s Lotriga
August 7, 2012
- Health Minister Komiyama Continues Requesting IPV Price Cut
August 6, 2012
- DTP-IPV to Be Introduced in November; MHLW Anticipates Supply of 1.47 Million Doses by End of FY2012
August 6, 2012
- Ratio of Generics Rises 0.3 Points to 23.8%: Survey
August 3, 2012
- PMDA Determines Role of Science Board to Enhance Review System
August 2, 2012
- Council Generally Approves Revised Basic Policy for 2nd Med. Expenditure Optimization Plan; Regional Targets for Use of Generics to Be Included
August 2, 2012
- MHLW Investigative Commission Compiles Report to Improve Distribution of Novel Influenza Vaccines
August 1, 2012
- Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
- MHLW to Issue Development Requests for 8 Drugs/Indications Determined to Have Unmet Medical Needs by Council on Unapproved Drugs
August 1, 2012
- MHLW Withdraws Development Request for Decitabine in Response to Approval for New Drug with Same Indication
August 1, 2012
- MHLW to Use Senshin-iryo System to Develop Anticancer Drugs from FY2013
July 30, 2012
- MHLW Approves Class 1 OTC Drugs for Allergic Rhinitis
July 30, 2012
- MHLW Reports Revisions of Package Insert for Telavic
July 27, 2012
- PAFSC’s 2nd Committee Recommends Approval of 2 DPT-IPV Vaccines; Introduction Expected in November
July 26, 2012
- PAFSC’s 2nd Committee Recommends Orphan Drug Designation for 3 Products Including Thyroid Cancer Treatment
July 26, 2012
- MHLW Asks Sanofi Pasteur to Consider Reducing Price of IPV
July 25, 2012
- MHLW Approves Revision to Kitasato Daiichi Sankyo Vaccine’s Management Resource Reuse Plan
July 25, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…